DE69815703D1 - Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen - Google Patents

Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen

Info

Publication number
DE69815703D1
DE69815703D1 DE69815703T DE69815703T DE69815703D1 DE 69815703 D1 DE69815703 D1 DE 69815703D1 DE 69815703 T DE69815703 T DE 69815703T DE 69815703 T DE69815703 T DE 69815703T DE 69815703 D1 DE69815703 D1 DE 69815703D1
Authority
DE
Germany
Prior art keywords
inactivating pathogens
compounds
methods
bindings
connections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815703T
Other languages
English (en)
Other versions
DE69815703T2 (de
Inventor
David Cook
John Merritt
Aileen Nerio
Henry Rapoport
Adonis Stassinopoulos
Susan Wollowitz
Jon Matejovic
William Denny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of DE69815703D1 publication Critical patent/DE69815703D1/de
Application granted granted Critical
Publication of DE69815703T2 publication Critical patent/DE69815703T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/64—Acridine or hydrogenated acridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69815703T 1997-01-06 1998-01-06 Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen Expired - Lifetime DE69815703T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77983097A 1997-01-06 1997-01-06
US77988597A 1997-01-06 1997-01-06
US779885 1997-01-06
US779830 1997-01-07
US4369697P 1997-04-15 1997-04-15
US43696P 1997-04-15
PCT/US1998/000532 WO1998030545A1 (en) 1997-01-06 1998-01-06 Frangible compounds for pathogen inactivation

Publications (2)

Publication Number Publication Date
DE69815703D1 true DE69815703D1 (de) 2003-07-24
DE69815703T2 DE69815703T2 (de) 2004-06-03

Family

ID=27366374

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815703T Expired - Lifetime DE69815703T2 (de) 1997-01-06 1998-01-06 Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen

Country Status (10)

Country Link
EP (1) EP1021414B1 (de)
JP (2) JP4551502B2 (de)
CN (2) CN101676268B (de)
AT (1) ATE243198T1 (de)
AU (1) AU744089C (de)
CA (1) CA2276532C (de)
DE (1) DE69815703T2 (de)
ES (1) ES2196530T3 (de)
HK (2) HK1188441A1 (de)
WO (1) WO1998030545A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744089C (en) * 1997-01-06 2003-07-31 Cerus Corporation Frangible compounds for pathogen inactivation
CN1203900C (zh) 1998-01-06 2005-06-01 塞鲁斯公司 用于淬灭生物材料中病原体灭活剂的方法
WO1999063981A2 (en) * 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
CN1436083A (zh) * 2000-05-31 2003-08-13 塞鲁斯公司 制备病原体灭活的低免疫原性红细胞溶液
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
AU2001298078A1 (en) * 2000-12-21 2003-09-02 Cerus Corporation Methods for inactivation of pathogens in biological materials
AU2004224425B2 (en) 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
ES2382332T3 (es) 2003-02-06 2012-06-07 Aduro Biotech Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN101094692A (zh) 2004-10-29 2007-12-26 塞鲁斯公司 用于红细胞灭活过程的改进的猝灭方法
WO2009126786A2 (en) 2008-04-09 2009-10-15 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3763710A1 (de) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutische verbindungen und verwendungen davon
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
ES2972443T3 (es) 2015-10-23 2024-06-12 Cerus Corp Plasma pobre en crioprecipitado inactivado para patógenos y métodos de uso del mismo
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN110268264B (zh) * 2016-12-23 2024-07-02 塞鲁斯公司 使用化合物结合的基材测试和筛选的***和方法
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
KR20200115498A (ko) 2017-12-29 2020-10-07 세루스 코포레이션 생물학적 유체를 처리하기 위한 시스템 및 방법
MX2021015653A (es) 2019-06-22 2022-04-11 Cerus Corp Sistemas de tratamiento de fluidos biologicos.
AU2020308035A1 (en) 2019-06-28 2022-02-17 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020090A1 (en) * 1993-03-17 1994-09-15 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
EP0773716A4 (de) * 1995-06-07 1999-08-04 Cerus Corp Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen
AU744089C (en) * 1997-01-06 2003-07-31 Cerus Corporation Frangible compounds for pathogen inactivation

Also Published As

Publication number Publication date
AU5821798A (en) 1998-08-03
JP5244083B2 (ja) 2013-07-24
HK1188441A1 (en) 2014-05-02
ATE243198T1 (de) 2003-07-15
DE69815703T2 (de) 2004-06-03
EP1021414A1 (de) 2000-07-26
WO1998030545A1 (en) 1998-07-16
JP2010095527A (ja) 2010-04-30
AU744089C (en) 2003-07-31
JP2001508449A (ja) 2001-06-26
EP1021414B1 (de) 2003-06-18
CA2276532A1 (en) 1998-07-16
AU744089B2 (en) 2002-02-14
JP4551502B2 (ja) 2010-09-29
CN1248245B (zh) 2012-07-04
HK1026702A1 (en) 2000-12-22
ES2196530T3 (es) 2003-12-16
CA2276532C (en) 2008-06-17
CN101676268B (zh) 2013-09-25
CN1248245A (zh) 2000-03-22
CN101676268A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
DE69815703D1 (de) Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen
ATE287210T1 (de) Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen
AU9058091A (en) Preparation of nucleic acid samples
DE69328685D1 (de) Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
AU2002305450A1 (en) Proteomimetic compounds and methods
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
GEP20022804B (en) Erythropoietin Derivatives
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
Balint et al. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment–A comparative study
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
BR9810242A (pt) Composições úteis como selante de fibrina
Jeong et al. Covalent interactions of toluenediisocyanate with DNA and proteins
AU6838400A (en) Use of colored metal binding proteins
UA23145A (uk) Спосіб визhачеhhя активhості бромелаїhу
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
ATE46360T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
AR007251A1 (es) Un metodo ''in vitro'' para inactivar un patogeno conteniendo rna en sangre de mamiferos y componentes de sangre de mamiferos y composicion de materiautilizada en el mismo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition